319 related articles for article (PubMed ID: 37430086)
41. Gene silencing by systemic delivery of synthetic siRNAs in adult mice.
Sørensen DR; Leirdal M; Sioud M
J Mol Biol; 2003 Apr; 327(4):761-6. PubMed ID: 12654261
[TBL] [Abstract][Full Text] [Related]
42. siRNA applications in nanomedicine.
Tokatlian T; Segura T
Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2010; 2(3):305-15. PubMed ID: 20135697
[TBL] [Abstract][Full Text] [Related]
43. A simplified and versatile system for the simultaneous expression of multiple siRNAs in mammalian cells using Gibson DNA Assembly.
Deng F; Chen X; Liao Z; Yan Z; Wang Z; Deng Y; Zhang Q; Zhang Z; Ye J; Qiao M; Li R; Denduluri S; Wang J; Wei Q; Li M; Geng N; Zhao L; Zhou G; Zhang P; Luu HH; Haydon RC; Reid RR; Yang T; He TC
PLoS One; 2014; 9(11):e113064. PubMed ID: 25398142
[TBL] [Abstract][Full Text] [Related]
44. Non-viral siRNA delivery to the lung.
Thomas M; Lu JJ; Chen J; Klibanov AM
Adv Drug Deliv Rev; 2007 Mar; 59(2-3):124-33. PubMed ID: 17459519
[TBL] [Abstract][Full Text] [Related]
45. Short interfering RNA (siRNA) as a novel therapeutic.
Pushparaj PN; Melendez AJ
Clin Exp Pharmacol Physiol; 2006; 33(5-6):504-10. PubMed ID: 16700886
[TBL] [Abstract][Full Text] [Related]
46. Novel approaches in cancer treatment: preclinical and clinical development of small non-coding RNA therapeutics.
Cuciniello R; Filosa S; Crispi S
J Exp Clin Cancer Res; 2021 Dec; 40(1):383. PubMed ID: 34863235
[TBL] [Abstract][Full Text] [Related]
47. Delivery systems for the direct application of siRNAs to induce RNA interference (RNAi) in vivo.
Aigner A
J Biomed Biotechnol; 2006; 2006(4):71659. PubMed ID: 17057369
[TBL] [Abstract][Full Text] [Related]
48. siRNA Therapeutics in Ocular Diseases.
Moreno-Montañés J; Bleau AM; Martínez T; Vargas B; González MV; Jiménez AI
Methods Mol Biol; 2021; 2282():417-442. PubMed ID: 33928588
[TBL] [Abstract][Full Text] [Related]
49. Developing a Versatile Shotgun Cloning Strategy for Single-Vector-Based Multiplex Expression of Short Interfering RNAs (siRNAs) in Mammalian Cells.
Wang X; Yuan C; Huang B; Fan J; Feng Y; Li AJ; Zhang B; Lei Y; Ye Z; Zhao L; Cao D; Yang L; Wu D; Chen X; Liu B; Wagstaff W; He F; Wu X; Luo H; Zhang J; Zhang M; Haydon RC; Luu HH; Lee MJ; Moriatis Wolf J; Huang A; He TC; Zeng Z
ACS Synth Biol; 2019 Sep; 8(9):2092-2105. PubMed ID: 31465214
[TBL] [Abstract][Full Text] [Related]
50. Mechanisms and optimization of in vivo delivery of lipophilic siRNAs.
Wolfrum C; Shi S; Jayaprakash KN; Jayaraman M; Wang G; Pandey RK; Rajeev KG; Nakayama T; Charrise K; Ndungo EM; Zimmermann T; Koteliansky V; Manoharan M; Stoffel M
Nat Biotechnol; 2007 Oct; 25(10):1149-57. PubMed ID: 17873866
[TBL] [Abstract][Full Text] [Related]
51. Pre-Clinical and Clinical Applications of Small Interfering RNAs (siRNA) and Co-Delivery Systems for Pancreatic Cancer Therapy.
Mirzaei S; Gholami MH; Ang HL; Hashemi F; Zarrabi A; Zabolian A; Hushmandi K; Delfi M; Khan H; Ashrafizadeh M; Sethi G; Kumar AP
Cells; 2021 Nov; 10(12):. PubMed ID: 34943856
[TBL] [Abstract][Full Text] [Related]
52. New short interfering RNA-based therapies for glomerulonephritis.
Shimizu H; Fujita T
Nat Rev Nephrol; 2011 May; 7(7):407-15. PubMed ID: 21610682
[TBL] [Abstract][Full Text] [Related]
53. Current Transport Systems and Clinical Applications for Small Interfering RNA (siRNA) Drugs.
Liu F; Wang C; Gao Y; Li X; Tian F; Zhang Y; Fu M; Li P; Wang Y; Wang F
Mol Diagn Ther; 2018 Oct; 22(5):551-569. PubMed ID: 29926308
[TBL] [Abstract][Full Text] [Related]
54. Preparation, Determination of Activity, and Biodistribution of Cholesterol-Containing Nuclease-Resistant siRNAs In Vivo.
Chernikov IV; Meschaninova MI; Chernolovskaya EL
Methods Mol Biol; 2020; 2115():57-77. PubMed ID: 32006394
[TBL] [Abstract][Full Text] [Related]
55. Hydrophobization and bioconjugation for enhanced siRNA delivery and targeting.
De Paula D; Bentley MV; Mahato RI
RNA; 2007 Apr; 13(4):431-56. PubMed ID: 17329355
[TBL] [Abstract][Full Text] [Related]
56. Chemical modification of siRNA.
Deleavey GF; Watts JK; Damha MJ
Curr Protoc Nucleic Acid Chem; 2009 Dec; Chapter 16():Unit 16.3. PubMed ID: 20013783
[TBL] [Abstract][Full Text] [Related]
57. Bio-inspired materials in drug delivery: Exploring the role of pulmonary surfactant in siRNA inhalation therapy.
De Backer L; Cerrada A; Pérez-Gil J; De Smedt SC; Raemdonck K
J Control Release; 2015 Dec; 220(Pt B):642-50. PubMed ID: 26363301
[TBL] [Abstract][Full Text] [Related]
58. A plasmid-based system for expressing small interfering RNA libraries in mammalian cells.
Kaykas A; Moon RT
BMC Cell Biol; 2004 Apr; 5():16. PubMed ID: 15119963
[TBL] [Abstract][Full Text] [Related]
59. Cell-internalization SELEX: method for identifying cell-internalizing RNA aptamers for delivering siRNAs to target cells.
Thiel WH; Thiel KW; Flenker KS; Bair T; Dupuy AJ; McNamara JO; Miller FJ; Giangrande PH
Methods Mol Biol; 2015; 1218():187-99. PubMed ID: 25319652
[TBL] [Abstract][Full Text] [Related]
60. Development of siRNA payloads to target KRAS-mutant cancer.
Yuan TL; Fellmann C; Lee CS; Ritchie CD; Thapar V; Lee LC; Hsu DJ; Grace D; Carver JO; Zuber J; Luo J; McCormick F; Lowe SW
Cancer Discov; 2014 Oct; 4(10):1182-1197. PubMed ID: 25100204
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
